Galectin Therapeutics In the Spotlight at MASH-TAG Conference
Galectin Therapeutics, Inc. (NASDAQ: GALT), a pioneering company focused on developing therapeutics targeting galectin proteins, is gearing up for a significant presentation during the upcoming 2025 MASH-TAG Conference. The conference, scheduled from January 9 to 11, 2025, will feature top-line results from the NAVIGATE trial, which explores the efficacy of belapectin in patients with MASH cirrhosis and portal hypertension.
Exciting Presentation Insights
The highlight of the conference for Galectin Therapeutics will be the oral presentation titled, "Belapectin administered at 2mg/kg/LBW for 18 months reduced the incidence of varices development in patients with MASH cirrhosis and portal hypertension: Top line results from the NAVIGATE trial." This informative session will be led by Dr. Naim Alkhouri, Chief Medical Officer at Arizona Liver Health.
Significant Outcomes from the NAVIGATE Trial
The NAVIGATE trial aims to shed light on the effectiveness of belapectin, the company's lead therapy, in mitigating the complications associated with MASH cirrhosis. With liver cirrhosis being a pressing medical concern, advancements in treatment options are crucial. This year’s conference will be an opportunity for sharing these pivotal findings with stakeholders in liver health and beyond.
Leadership Engagement Opportunities
In addition to the MASH-TAG Conference, executives from Galectin Therapeutics will be available for one-on-one meetings in San Francisco during the JP Morgan Healthcare Conference from January 13 to 16, 2025. These discussions will focus on not just the NAVIGATE trial results, but also the broader development strategy for the belapectin program, which holds promise for various liver diseases.
About Galectin Therapeutics
Galectin Therapeutics is dedicated to pioneering novel therapies designed to enhance the quality of life for patients suffering from chronic liver diseases and cancer. The company's hallmark drug, belapectin, targets the galectin-3 protein, involved in numerous inflammatory, fibrotic, and malignant disorders. The FDA has granted Fast Track designation to belapectin for its potential in treating metabolic dysfunction-associated steatohepatitis (MASH), emphasizing its importance in addressing liver fibrosis.
Leveraging Partnerships for Progress
Looking ahead, Galectin Therapeutics is committed to advancing additional development programs, which include combined immunotherapy approaches for advanced cancers. A key element for this growth is securing strong partnerships that will facilitate efficient and effective drug development, ensuring that patients receive timely access to next-generation therapies.
Company Contact Information
For inquiries, the company encourages reaching out to:
Jack Callicutt, Chief Financial Officer
(678) 620-3186
Email: ir@galectintherapeutics.com
For investor relations, contact:
Kevin Gardner
Email: kgardner@lifesciadvisors.com
Chris Calabrese
Email: ccalabrese@lifesciadvisors.com
Frequently Asked Questions
What is the NAVIGATE trial about?
The NAVIGATE trial investigates the effectiveness of belapectin in patients with MASH cirrhosis and portal hypertension.
Who will present at the MASH-TAG Conference?
Dr. Naim Alkhouri will present the NAVIGATE trial's findings at the conference.
What does belapectin target?
Belapectin targets the galectin-3 protein, which plays a key role in various diseases, including chronic liver disease.
When is the one-on-one meeting opportunity with Galectin Therapeutics?
The one-on-one meetings will take place from January 13-16, 2025, during the JP Morgan Healthcare Conference in San Francisco.
How can I contact Galectin Therapeutics?
You can reach out directly via their investor relations email or call their CFO Jack Callicutt at (678) 620-3186.
